PND42 Burden of Disease in Caregivers of Alzheimer's Disease in Brazil: Results From 2011 National Health and Wellness Survey (NHWS)  by Mould, J.F. et al.
acteristics, treatments, symptoms, seizure frequency and severity as well as com-
plete Patient Reported Outcomes (PRO) instruments (e.g. QOLIE-31/P, HADS). Uni-
variate and multivariate logistic regressions were performed to identify variables
associated with poor HRQoL (Quartile 1 of the QOLIE-31/P total score). RESULTS:
By May 2011, of the 2658 patients who had recorded a diagnosis of epilepsy and
multiple seizures, 1025 completed a PRO assessment and were included in this
analysis (mean age 37.5 years; 72.7% female; mean epilepsy duration from first
diagnosis 17.5 years). Median Q1-Q3 QOLIE-31/P total score was 50.5 (37.1-65.2),
with 256 patients being classifiedwith poor HRQoL. Multivariate logistic regression
indicated that poor HRQoL was more likely in patients reporting (Odds Ratio [95%
Confidence Interval]): 1)moderate/severe problems concentrating (3.19 [2.00-5.08]),
depression (2.61 [1.77-3.85]), memory problems (2.04 [1.29-3.24]), fatigue (1.75 [1.12-
2.71]), anxiety (1.49 [1.00-2.22]); 2) severe side effects (2.34 [1.39-3.92]); 3) at least one
tonic-clonic seizure during the 4 weeks before QOLIE-31/P completion (2.72 [1.65-
4.50]); 4) age 25-50 years (1.77 [1.01-3.11] vs. age 0-25 years); and 5) shorter epilepsy
duration (1 year 2.25 [1.23-4.13]; 1-10 years 1.70 [1.12-2.58]; both vs. 10 years).
Patients on polytherapy with newer antiepileptic drugs (AEDs) were less likely to
report poor HRQoL than patients on polytherapy with older AEDs (0.29 [0.11-0.74]).
CONCLUSIONS: These analyses indicate that moderate/severe problems concen-
trating, depression, the occurrence of generalized tonic-clonic seizures and of se-
vere side effects were the most predictive factors of poor HRQoL in the Patients-
LikeMe EpilepsyCommunity. These results suggest that a holistic approach beyond
seizure control should be considered when treating people with epilepsy.
PND38
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OBJECTIVES:Walking impairment (WI) is a disabling hallmark ofmultiple sclerosis
(MS). This patient-centric study aimed to assess the clinical, psychological, and
economic burden of WI. METHODS: This cross-sectional study compared MS pa-
tients with (test group: TG, PDDS0) and without (control group: CG,PDDS0). WI
as assessed by the Patient Determined Disease Steps (PDDS) questionnaire.
PDDS3 describes patients with mild WI while PDDS4 reflects patients using a
walking device. Using validated patient-reported outcomes instruments, falls, de-
pression (Center for Epidemiologic Studies Depression Scale) resource utilization,
and work productivity (Work Productivity and Activity Impairment Questionnaire)
were assessed. Chi-square and t-test provided statistical significance to p0.01.
RESULTS: 346 adult MS patients around 11 years post-diagnosis participated. WI
was significantly different across groups (TG:PDDS3.2vs.CG:PDDS0). In the TG,
patients with WI using a device reported more healthcare visits for WI than pa-
tients with mild WI (PDDS4:58%vs.PDDS3:13%). TG patients reported “falling
sometimes” significantly more than CG patients (PDDS3:62%; PDDS4:50% vs.
PDDS0:14%). Compared to CG patients, more PDDS3 TG patients reported visit-
ing the hospital/ER (11% vs. 5%) or doctor’s office (16%vs.5%) for falls. WI requiring
the use of a device (PDDS4) increased the reportedhealthcare visits (32%:hospital/
ER;27%:doctor’s visits). TG patients reported depression significantlymore than CG
patients and 40% of these TG patients explicitly linked depression to WI. Absen-
teeism (10%vs.5%) and impairmentwhile working (35%vs.18%)were reportedmore
often in TG compared to CG patients. CONCLUSIONS: In this sample, WI was as-
sociated with increased falls, health care utilization, depression and lesser work
productivity. WI requiring use of a device appears to increase these effects. WI
effects could not fully be isolated from cognitive impairment and other effects, and
confounding by indication could affect estimates. Multivariate model research is
needed to validate these results in a broader population and quantify associated
costs.
PND39
WHAT IS THE INFLUENCE ON CLINICAL RESEARCH OF THE EMA GUIDELINE ON
MEDICINAL PRODUCTS FOR THE TREATMENT OF ALZHEIMER’S DISEASE?
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OBJECTIVES: In 2009, the EMA published a guideline onmedicinal products for the
treatment of Alzheimer’s disease. The guideline stipulates that symptoms im-
provement should be assessed in cognition (cognitive endpoint), activities of daily
living (functional endpoint) and overall clinical response (global endpoint). The two
primary endpoints should reflect the cognitive and functional domains. Global
assessment should be evaluated as a secondary endpoint. The objective of this
study is to review all products authorized by the EMA for the treatment of Alzhei-
mer’s before and after the publication of the guidance to see if the guidance had
any influence on clinical research or is only making existing practices official.
METHODS: The EMA website was searched with the keyword “Alzheimer” (EPAR
section, Keyword search). All EPARs and Scientific Discussions corresponding to
Alzheimer’s medicines were downloaded and reviewed. RESULTS: Ten products
were retrieved representing only two active substances: rivastigmine (8), and me-
mantine hydrochloride (2). Fourmedicineswere approved before the publication of
the guidance, and six afterwards (all generics of rivastigmine). The review of the
rivastigmine documents shows that the same studies were used for all products,
and that primary endpoints were cognitive and global; functional was secondary.
The review of the memantime documents shows that the same studies were used
for all products. For two studies, the EMA advised the sponsors that primary end-
points should be functional and global; cognitive was secondary. For two other
studies, global and cognitive measures were primary endpoints; functional was
secondary.CONCLUSIONS: Before 2009, symptoms improvement is assessed in the
three recommended domains. The primary and secondary endpoints, however,
were not always consistent with those advised by the guideline, and sometimes
contradicted them. The review cannot show any influence of the guidance on
clinical research since all products approved after its publication are generics of
rivastigmine.
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OBJECTIVES: Tomake an assessment of cognitive abilities of caregivers of individ-
uals with Alzheimer’s disease and to determine the risk of developing dementia in
this population. METHODS: A cross-sectional research design, utilizing a conve-
nience sample and one-on-one interviews, was adopted to address the study ob-
jectives. Family caregivers were recruited from New York City caregiver support
groups. Cognitive Abilities Screening Instrument (CASI), a pre-validated cognitive
scale, was used to assess the risk of dementia among the caregivers and a demo-
graphically similar sample of non-caregivers. CASI tests nine cognitive domains,
and a score of  74 on a scale between 1 and 100 indicates possible cognitive
impairment. The component scores of CASI were utilized to derive Mini Mental
State Examination (MMSE-CE) scores. Both MMSE-CE and individual component
scores of CASI were compared for the caregiver and non-caregiver groups.
RESULTS: The final data set consisted of 51 caregivers and 62 non-caregivers. Sig-
nificant differences were observed between the two with respect to CASI score (t
-2.311, p 0.001), MMSE-CE score (t -1.943, p 0.013) and individual domain
scores. Prevalence and number of medical conditions seemed to affect caregivers’
cognitive performance more than the non caregivers. Further, age and duration of
caregiving were revealed to be significant predictors of dementia risk in the care-
giver population based on both binary logistic (OR10.706, P 0.027,) andmultiple
linear regression (-0.306, P 0.028) models. CONCLUSIONS: This study provides
insights regarding the impact of caregiving on Alzheimer’s caregivers, specifically
with respect to their cognitive functioning. There is a greater likelihood of family
caregivers experiencing cognitive decline, significantly raising their risk of devel-
oping dementia sometime in the future. Health interventions should be designed
to make caregivers aware of the risks they face if they neglect their own health in
the process of caregiving.
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OBJECTIVES: To assess whether combined surgery and best medical therapy re-
sulted in better outcomes than best medical therapy alone, in patients with ad-
vanced Parkinson’s disease (PD).METHODS: The PD SURG trial is an ongoing ran-
domised, open-label trial. At 13 neurosurgical centres in the UK, between
November 2000, and December 2006, patients with PD (that was not adequately
controlled bymedical therapy) were assigned to either, combined surgery and best
medical therapy, or to best medical therapy alone. The primary endpoint was the
quality of life PRO measure, the 39-item Parkinson’s disease questionnaire (PDQ-
39). Changes between baseline and 1 year were compared by use of t tests.
RESULTS: 366 patients were randomly assigned to receive immediate surgery and
bestmedical therapy (183) or bestmedical therapy alone (183). All patientswhohad
surgery had deep brain stimulation. At 1 year, the mean improvement in PDQ-39
summary index score compared with baseline was 5.0 points in the surgery group
and 0·3 points in the medical therapy group (difference –4·7, 95% CI –7·6 to –1·8;
p0.001); the difference in mean change in PDQ-39 score in the mobility domain
between the surgery group and the best medical therapy group was –8·9 (95% CI
–13·8 to –4·0; p0.0004), in the activities of daily living domain was –12·4 (–17·3 to
–7·5; p0.0001), and in the bodily discomfort domain was –7·5 (–12·6 to –2·4;
p0.004). Differences between groups in all other domains of the PDQ-39 were not
significant. Other serious adverse events will be reported. CONCLUSIONS: At one
year, surgery and best medical therapy improved patient self-reported quality of
life more than best medical therapy alone in patients with advanced Parkinson’s
disease. These differences are clinicallymeaningful, but surgery is not without risk
and targeting of patients most likely to benefit might be warranted.
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OBJECTIVES: Alzheimer’s disease (AD) is the most common type of dementia for
which there is no cure. In a world where lifespan is increasing, dementia is becom-
ing more evident. In 2010, approximately 35.6 million people were living with de-
mentia and this number is likely to increase to 115.4 million in 2050. This study is
aimed to assess co-morbidity, quality of life (QOL), work/productivity loss, and
medical resource utilization in caregivers of AD in Brazil. METHODS: A total of
12,000 individuals’ (age 18) self-reported data were collected from 2011 National
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Health andWellness Survey (NHWS) in Brazil.. QOL was measured by the physical
component score (PCS) and mental component score (MCS) of the Short Form-12
(SF-12). Loss of work/productivity was measured by the validated Work Productiv-
ity and Activity Impairment instrument. Medical resource utilization was mea-
sured by health care provider, emergency room visits and hospitalization in the
past 6 months. RESULTS: Of the 12,000 respondents, 215 (1.6%) were identified as
AD patient’s caregivers where 63.7% were women. The age group with the highest
proportion of caregivers was 45-54yrs old (36.2%), and they are significantly older
than non-caregivers (44.7 vs. 40.8, p0.05). AD caregivers group reported more
specific co-morbidities (insomnia 33.8%, cardiac arrhythmia 20.7%), similar mean
scores of PCS (49.8 vs. 49.7) andMCS (47.3 vs. 46.9), similar percentage of emergency
roomvisits (21.5% vs. 21.8%), and similar percentage of hospitalization visits (9.9 vs.
9.8) over the past 6months compared to the group of not caregivers of AD patients.
Furthermore, caregivers of AD patients’ group reported 22.3% impairment in daily
activity compared to 22.1% in the group of not caregivers of AD patients.
CONCLUSIONS: From the Brazil NHWS results, AD caregivers suffer from impair-
ment in QOL, work/productivity loss and more specific co-morbidities. Findings
indicate there is still an unmet medical need in AD caregivers in Brazil.
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OBJECTIVES: The majority of currently approved disease-modifying therapies for
Multiple Sclerosis (MS) are injectables; however, there is no validated injection
satisfaction questionnaire for patients with MS. The Satisfaction with Injection
Experience (SIE) questionnaire was developed as a reliable and valid scale to eval-
uate this critical aspect of MS treatment satisfaction. METHODS: The medical lit-
erature was reviewed to determine the domains that were relevant to MS injection
satisfaction. Five domains were identified, along with the most commonly used
response options and recall period. A draft SIE questionnaire was evaluated in
cognitive debriefing interviews with MS patients. The final 5-item SIE question-
naire utilized a 2-week recall period, a 5-point Likert scale, and was scored as an
unweighted mean composite with higher scores representing greater satisfaction.
Preliminary psychometric analyses were conducted using baseline data from EN-
CORE, a multicenter clinical trial designed to investigate 2 formulations of glati-
ramer acetate (GA) for subcutaneous injection. Data were analyzed using item-
total Spearman correlations, Cronbach’s alpha, and principal components
analysis.RESULTS:Complete datawere available for 142MSpatientswhohad been
on the currentlymarketed 20mg formulation of GA utilizing the autoject 2 for glass
syringe for at least 90 days (mean 4.8 years; SD 3.6). The mean score on the SIE
questionnaire was 4.1 (SD  0.8; range 1.0 to 5.0). All item-total Spearman correla-
tions were greater than 0.30 (range 0.34 to 0.79) and the SIE questionnaire demon-
strated excellent overall internal reliability (Cronbach’s alpha 0.82). Based on the
eigenvalues and scree plot of the principal components analysis, a single compo-
nent was extracted, with 58.6% of total variation explained. CONCLUSIONS: The
5-item SIE questionnaire exhibited good psychometric properties, including evi-
dence of reliability and content validity. Furthermore, this sample of MS patients,
who were long-term users of GA, reported high levels of satisfaction with their
injection experience.
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OBJECTIVES: To assess in short-term changes in employment status in relapsing-
remittingmultiple sclerosis (RRMS) patients are treated with either oral, once daily
placebo, once daily Laquinimod 0.6mg or weekly intramuscular (IM) injections of
Interferon beta 1a. METHODS: Patients residing within the United States (n  xx)
with RRMS and Expanded Disability Status Scale (EDSS)  5.5 were randomly as-
signed to receive Laquinimod 0.6mg once daily, oral placebo once daily or Inter-
feron -1a 30mcg intramuscular injection weekly in the randomized, placebo con-
trolled BRAVO trial. U.S. patients completed the validated Work Productivity and
Activity Impairment Scale-General Health (WPAI-GH) at baseline and every three
months thereafter. At study completion, patient’s transitions from 1) unemploy-
ment to employment; 2) no transition in employment; and 3) transitions from
unemployment to employment were assessed using univariate statistics.
RESULTS: Sixty-two patients residing in the United States completed theWPAI-GH
with comparable study populations assigned to each of the three study arms. Sta-
tistically significant differences were observed across the three treatment arms
when consideration was given to changes in employment status (p  0.001). Sev-
enty-seven percent of patients treatedwith Avonex reported no change in employ-
ment status during the course of the study while 81% of patients in each of the
Laquinimod or placebo arm reported no change. Patients enrolled in the Avonex
group report the greatest transition from employment to unemployment (18%)
compared to Laquinimod (9%) and placebo (6%). CONCLUSIONS: Managed care
pharmacists consider multiple factors when making formulary decisions. While
safety and efficacy are the primary considerations, other factors that influence
patients and employers are frequently evaluated. While exploratory in nature,
variations in changes in employment status may occur in RRMS patients treated
with alternative diseasemodifying therapies. These findings, however, are prelim-
inary in nature and warrant future consideration through additional research.
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OBJECTIVES: Emerging data suggest that even mild or subclinical mobility loss
associated withmultiple sclerosis (MS) may adversely affect health-related quality
of life (HrQoL). We evaluated the impact and timing of mobility impairment on
HrQoL. METHODS: The North American Committee on Multiple Sclerosis (NAR-
COMS) registry was used to conduct a cross-sectional study of participants who
completed the biannual update and supplemental Spring 2010 surveys. The NAR-
COMS Performance Scale for mobility was used to grade severity of mobility im-
pairment. HrQoL assessments included the Short Form(SF)-12, physical andmental
subscales (PCS and MCS), the EuroQoL (EQ)-5D, EQ-Visual Analog Scale (VAS), and
SF-6D. RESULTS: A total of 3483 registrants completed both surveys. Compared
with those rating themselves as “normal” (n628) on the mobility performance
scale, participants describing their disability as “minimal” (n566), “mild” (n535),
“occasional support usage” (n535), “frequent cane usage” (n527), “severe”
(n543), and “total” (n105) each reported poorer HrQoL scores on the PCS and
MCS (PCS range: 53.6-30.5, MCS range: 46.8-40.3; p0.001 for all). The largest rela-
tive decrement in PCS andMCS came at the transition from “normal” to “minimal”
(PCS: 15.1%, MCS: 6.2%) and “minimal” to “mild” mobility impairment (PCS: 15.4%,
MCS: 5.9%), with the detrimental effect of poorer mobility more profound on the
PCS, and little effect on the MCS after the earlier stages of mobility impairment.
Poorer health utility was also reported in participants in impairedmobility catego-
ries compared to “normal” when examined using each of the utility measures
(EQ-5D range: 0.89-0.53, EQ-VAS range: 0.83-0.55, SF-6D range: 0.78-0.58; p0.001
for all). The largest decrements in utility came at the transition from “normal” to
“minimal” (9.6%-10.3%) and “minimal” to “mild” mobility impairment (an addi-
tional 8.6%-10.7%). CONCLUSIONS: These data suggest that mobility impairment
may negatively affect HrQoL, with the most profound decrements occurring at
earlier stages of mobility loss.
PND46
LONGITUDINAL ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN AN
OBSERVATIONAL COHORT OF PATIENTS WITH CYSTIC FIBROSIS
Sawicki GS1, Rasouliyan L2, Mcmullen AH3, Wagener JS4, Mccolley SA5, Pasta DJ6,
Quittner AL7
1Children’s Hospital Boston, Boston, MA, USA, 2ICON Late Phase & Outcomes Research,
Barcelona, Catalonia, Spain, 3University of Rochester, Rochester, NY, USA, 4University of
Colorado School of Medicine, Denver, CO, USA, 5Northwestern University Feinberg School of
Medicine, Chicago, IL, USA, 6ICON Late Phase & Outcomes Research, San Francisco, CA, USA,
7University of Miami, Miami, FL, USA
OBJECTIVES: To evaluate associations between changes in health status over time
and health-related quality of life (HRQOL) using the Cystic Fibrosis Questionnaire-
Revised (CFQ-R), a disease-specific patient-reported outcome (PRO) measure of
HRQOL. METHODS: Using the Epidemiologic Study of Cystic Fibrosis (ESCF) data,
we identified participants who had completed age-appropriate CFQ-R assessments
on 2 occasions separated by 9 to 15months.We developedmultivariable regression
models to test whether associations existed between 1) changes in respiratory
signs/symptoms and changes in the respiratory health domains of the CFQ-R; 2)
changes in nutritional health status and changes in the nutritional health domains
of the CFQ-R; and 3) changes in treatment complexity and changes in the Treat-
ment Burden scale of the CFQ-R. RESULTS:Weanalyzed 1947 pairs of assessments:
337 child (8.9, range 6-13 years), 581 parent (mean age of child 8.8, range 6-13 years),
398 adolescent (mean age 15.3, range 14-17 years), and 631 adult (mean age 26.9,
range 18-73 years). On average, we found little change in both health status indi-
cators and CFQ-R domain scores over 1 year. Significant associations over time,
however, were found with declining weight and worsening scores on the CFQ-R
nutritional health domains, and increases in treatment complexity and worsening
CFQ-R Treatment Burden scores for parent respondents. CONCLUSIONS: Health
status and HRQOL changes were small over a 1-year period in this CF population.
Changes in respiratory symptoms and weight, however, were associated with sig-
nificant changes on relevant CFQ-R scores, indicating that this PRO is sensitive to
changes in health status over time.
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OBJECTIVES: This post hoc analysis evaluated the use of rescue medication in the
acute treatment of migraine episodes reported during a randomized, placebo-con-
trolled, double-blind trial of MAP0004, an investigational, orally inhaled
dihydroergotamine. METHODS: Rescue medication use (RMU) was permitted in
this study if migraine symptomswere not relieved 2 hours after study drug admin-
istration. RMU in the MAP0004 and placebo treatment groups were adjusted for
baseline pain scores and compared according to demographic and baseline disease
characteristics (eg, age, gender, race, migraine history, baseline pain severity). The
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